Friday, 20 Apr 2018

You are here

Registry Efficacy of Rituximab in Refractory SLE

Rituximab (RTX) treatment of lupus (SLE) patients remains a therapeutic option, especially in refractory SLE.  An observational UK cohort of 261 refractory SLE patients were followed in the BILAG-BR registry.

Patients starting biologic therapy between 2010 and 2015 were enrolled. Glucocorticoids were used in 93% of patients.

Response rates at 6 months were available for 68% of patients. After 6 mos. of RTX, median BILAG scores dropped from at baseline to 3 at 6 months (P < 0.0001).

During the same period the median SLEDAI-2K reduced from 8 to 4 (0-7) (P < 0.001).

Half (49%) of patients achieved a response along with a significant reduction of glucocorticoid dose to 7.5 mg at 6 months (P < 0.001).

Serious infections occurred in 10% patients.

Despite large randomized trials failing to show the efficacy of RTX in SLE (LUNAR https:/buff.ly/2BDE725 and EXPLORER https://buff.ly/2BCHy99), uncontrolled observational data suggests possible efficacy and safety of RTX in refractory SLE.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Wear Your Pajamas to Work for Lupus

I suspect that everyone in rheumatology has a special place in their hearts for lupus patients. Their disease is so cruel, and we have so little to offer them, but the young women (and some men) that I treat keep battling on. The longer I have cared for them, the more I wanted to do for them. Managing their illness alone did not seem like enough. 

SynBioSe: Combo Rituximab and Belimumab Succeeds in Severe Refractory Lupus

One of the driving pathogenic mechanisms in systemic lupus erythematosus (SLE) is the generation of immune complexes capable of inducing netosis (NET formation) and NET-derived DNA that may be an amplifying autoantigen and give rise to anti-nuclear autoantibodies (ANAs). 

Increased Comorbidity Burden in Lupus African Americans

Researchers from Vanderbilt University Medical Center used electronic health records (EHR) to perform a phenome-wide study comparing African American (AA-SLE) and Caucasian (C-SLE) with systemic lupus erythematosus (SLE) and found more comorbidities in AA-SLE, especially renal, cardiovascular, and infectious diseases.

The Consequences and Cure of Hepatitis C

I spent this past week seeing hepatitis C patients with our hepatologists, and being a rheumatologist, I was looking forward to seeing extra-hepatic manifestations of HCV that we read about in text-books - cryoglobulinemic vasculitis, sicca syndrome, porphyria cutanea tarda and many others. I suppose I should not be surprised that the week passed without seeing a single one of these. 

mTOR Inhibition with Sirolimus Effective in Lupus

Lancet reports that 12 months of sirolimus treatment is associated with improvement in lupus disease activity presumeably by correction of pro-inflammatory T-cell activity.